BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wienke J, Deakin CT, Wedderburn LR, van Wijk F, van Royen-Kerkhof A. Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools. Front Immunol 2018;9:2951. [PMID: 30619311 DOI: 10.3389/fimmu.2018.02951] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, Jain M, Adeojo LW, George J, Perez M, Grom AA, Sutter M, Feldman BM, Yao L, Millwood M, Brundidge A, Pichard DC, Cowen EW, Shi Y, Lu S, Tsai WL, Gadina M, Rider LG, Colbert RA. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis 2020:annrheumdis-2020-218690. [PMID: 32843325 DOI: 10.1136/annrheumdis-2020-218690] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
2 Mammen AL, Allenbach Y, Stenzel W, Benveniste O; ENMC 239th Workshop Study Group. 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. Neuromuscul Disord 2020;30:70-92. [PMID: 31791867 DOI: 10.1016/j.nmd.2019.10.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
3 McCann LJ, Hedrich CM. Is it time to re-think juvenile-onset Rheumatic and Musculoskeletal Diseases? - First steps towards individualised treatments to meet agreed targets. Clin Immunol 2021;223:108647. [PMID: 33310069 DOI: 10.1016/j.clim.2020.108647] [Reference Citation Analysis]
4 Wienke J, Bellutti Enders F, Lim J, Mertens JS, van den Hoogen LL, Wijngaarde CA, Yeo JG, Meyer A, Otten HG, Fritsch-Stork RDE, Kamphuis SSM, Hoppenreijs EPAH, Armbrust W, van den Berg JM, Hissink Muller PCE, Tekstra J, Hoogendijk JE, Deakin CT, de Jager W, van Roon JAG, van der Pol WL, Nistala K, Pilkington C, de Visser M, Arkachaisri T, Radstake TRDJ, van der Kooi AJ, Nierkens S, Wedderburn LR, van Royen-Kerkhof A, van Wijk F. Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation. Arthritis Rheumatol 2019;71:1377-90. [PMID: 30861625 DOI: 10.1002/art.40881] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
5 Wienke J, Pachman LM, Morgan GA, Yeo JG, Amoruso MC, Hans V, Kamphuis SSM, Hoppenreijs EPAH, Armbrust W, van den Berg JM, Hissink Muller PCE, Gelderman KA, Arkachaisri T, van Wijk F, van Royen-Kerkhof A. Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis. Arthritis Rheumatol 2020;72:1214-26. [PMID: 32103637 DOI: 10.1002/art.41236] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
6 Wienke J, Mertens JS, Garcia S, Lim J, Wijngaarde CA, Yeo JG, Meyer A, van den Hoogen LL, Tekstra J, Hoogendijk JE, Otten HG, Fritsch-Stork RDE, de Jager W, Seyger MMB, Thurlings RM, de Jong EMGJ, van der Kooi AJ, van der Pol WL, Arkachaisri T, Radstake TRDJ, van Royen-Kerkhof A, van Wijk F; Dutch Juvenile Myositis Consortium. Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk. Rheumatology (Oxford) 2021;60:785-801. [PMID: 32810267 DOI: 10.1093/rheumatology/keaa270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Pachman LM, Nolan BE, DeRanieri D, Khojah AM. Juvenile Dermatomyositis: New Clues to Diagnosis and Therapy. Curr Treatm Opt Rheumatol 2021;7:39-62. [PMID: 34354904 DOI: 10.1007/s40674-020-00168-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang X, Ding Y, Zhou Z, Hou J, Xu Y, Li J. Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children. Pediatr Rheumatol Online J 2021;19:6. [PMID: 33407621 DOI: 10.1186/s12969-020-00492-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Xu Q, Li QX, Bi FF, Duan HQ, Luo YB, Yang H. The association between myositis-specific autoantibodies and muscle pathologies in idiopathic inflammatory myopathies. Clin Rheumatol 2021;40:613-24. [PMID: 32671659 DOI: 10.1007/s10067-020-05274-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Tawalbeh SM, Marin W, Morgan GA, Dang UJ, Hathout Y, Pachman LM. Serum protein biomarkers for juvenile dermatomyositis: a pilot study. BMC Rheumatol 2020;4:52. [PMID: 33015544 DOI: 10.1186/s41927-020-00150-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Moegle C, Lipsker D. [Juvenile dermatomyositis: A series of 22 cases]. Ann Dermatol Venereol 2020;147:494-503. [PMID: 32532518 DOI: 10.1016/j.annder.2020.04.016] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Kwiatkowska D, Reich A. The Significance of Autoantibodies in Juvenile Dermatomyositis. Biomed Res Int 2021;2021:5513544. [PMID: 34840975 DOI: 10.1155/2021/5513544] [Reference Citation Analysis]
13 Ouyang S, Liu Y, Xiao C, Zeng Q, Luo X, Hu X, Xie S. Identification of Latent Diagnostic Biomarkers and Biological Pathways in Dermatomyositis Based on WGCNA. J Oncol 2021;2021:1920111. [PMID: 35003257 DOI: 10.1155/2021/1920111] [Reference Citation Analysis]
14 McLellan K, Papadopoulou C. Update on Biomarkers of Vasculopathy in Juvenile and Adult Myositis. Curr Rheumatol Rep 2022. [PMID: 35680774 DOI: 10.1007/s11926-022-01076-4] [Reference Citation Analysis]
15 Yang CA, Chiang BL. Inflammasomes and Childhood Autoimmune Diseases: A Review of Current Knowledge. Clin Rev Allergy Immunol 2021;61:156-70. [PMID: 33236284 DOI: 10.1007/s12016-020-08825-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kim H. Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy. Curr Opin Rheumatol 2021;33:371-7. [PMID: 34230439 DOI: 10.1097/BOR.0000000000000816] [Reference Citation Analysis]
17 Schänzer A, Rager L, Dahlhaus I, Dittmayer C, Preusse C, Della Marina A, Goebel HH, Hahn A, Stenzel W. Morphological Characteristics of Idiopathic Inflammatory Myopathies in Juvenile Patients. Cells 2021;11:109. [PMID: 35011672 DOI: 10.3390/cells11010109] [Reference Citation Analysis]
18 Di Donato G, d'Angelo DM, Breda L, Chiarelli F. Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives. Int J Mol Sci 2021;22:6360. [PMID: 34198614 DOI: 10.3390/ijms22126360] [Reference Citation Analysis]
19 Diniz MFR, Kozu KT, Elias AM, Lianza AC, Sawamura KSS, Menezes CRB, Ferreira JCOA, Silva CA, Leal GN. Echocardiographic study of juvenile dermatomyositis patients: new insights from speckle-tracking-derived strain. Clin Rheumatol 2021;40:1497-505. [PMID: 32989504 DOI: 10.1007/s10067-020-05418-4] [Reference Citation Analysis]
20 Ll Wilkinson MG, Deakin CT, Papadopoulou C, Eleftheriou D, Wedderburn LR. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. Pediatr Rheumatol Online J 2021;19:146. [PMID: 34563217 DOI: 10.1186/s12969-021-00637-8] [Reference Citation Analysis]
21 Dvergsten JA, Reed AM, Landerman L, Pisetsky DS, Ilkayeva O, Huffman KM. Metabolomics Analysis Identifies a Lipidomic Profile in Treatment Naïve Juvenile Dermatomyositis Patients versus Healthy Control Subjects. Rheumatology (Oxford) 2021:keab520. [PMID: 34185053 DOI: 10.1093/rheumatology/keab520] [Reference Citation Analysis]
22 Melki I, Devilliers H, Gitiaux C, Bondet V, Belot A, Bodemer C, Quartier P, Crow YJ, Duffy D, Rodero MP, Bader Meunier B. Circulating Interferon‐α Measured With a Highly Sensitive Assay as a Biomarker for Juvenile Inflammatory Myositis Activity: Comment on the Article by Mathian et al. Arthritis Rheumatol 2019;72:195-7. [DOI: 10.1002/art.41096] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
23 Schildt EE, De Ranieri D. Anasarca as the presenting symptom of juvenile dermatomyositis: a case series. Pediatr Rheumatol Online J 2021;19:120. [PMID: 34389019 DOI: 10.1186/s12969-021-00604-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Stenzel W, Goebel HH, Bader-Meunier B, Gitiaux C. Inflammatory myopathies in childhood. Neuromuscul Disord 2021;31:1051-61. [PMID: 34736626 DOI: 10.1016/j.nmd.2021.08.007] [Reference Citation Analysis]
25 Bonomo AC, Pinto-Mariz F, Riederer I, Benjamim CF, Butler-Browne G, Mouly V, Savino W. Crosstalk Between Innate and T Cell Adaptive Immunity With(in) the Muscle. Front Physiol 2020;11:573347. [PMID: 33071827 DOI: 10.3389/fphys.2020.573347] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Qiu CC, Su QS, Zhu SY, Liu RC. Identification of Potential Biomarkers and Biological Pathways in Juvenile Dermatomyositis Based on miRNA-mRNA Network. Biomed Res Int 2019;2019:7814287. [PMID: 31886250 DOI: 10.1155/2019/7814287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Heinen A, Schnabel A, Brück N, Smitka M, Wolf C, Lucas N, Dollinger S, Hahn G, Günther C, Berner R, Lee-kirsch M, Schuetz C. Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis? Rheumatology 2021;60:e136-8. [DOI: 10.1093/rheumatology/keaa657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]